Yessayan, Lenar
Sohaney, Ryann
Puri, Vidhit
Wagner, Benjamin
Riddle, Amy
Dickinson, Sharon
Napolitano, Lena
Heung, Michael
Humes, David
Szamosfalvi, Balazs
Article History
Received: 10 February 2021
Accepted: 28 May 2021
First Online: 2 July 2021
Declarations
:
: The study was approved by Institutional Review Board of University of Michigan (IRB # HUM00029545) and informed consent has been waived for reasons that include the observational nature of the study and the feasibility constraint of obtaining consent from all patients triaged to the protocol. All methods were carried out in accordance with relevant guidelines and regulations.
: All authors consent to publish. There are no clinical details of participants or publication of identifying images or other personal data that compromise anonymity
: M. Heung reports Consultancy Agreements: Potrero Medical, Inc., Baxter Inc., Wolters Kluwer (Lexicomp); Research Funding: VA, CDC, PCORI; Honoraria: NKF; Scientific Advisor or Membership: Associate Editor/Editorial board, Advances in Chronic Kidney Disease. H. Humes reports Consultancy Agreements: SeaStar Medical; Ownership Interest: Innovative BioTherapies, Inc., SeaStar Medical, Inc.; Research Funding: Innovative Biotherapies, Renal Research Institute, SeaStar Medical, Sygin, Lowell Pharmaceuticals; Scientific Advisor or Membership: Innovative Biotherapies, SeaStar Medical. B. Szamosfalvi reports Research Funding: Renal Research Institute. B. Wagner reports Ownership Interest: Able-Wagner, Inc. Lenar Yessayan reports Scientific Advisor or Membership: Section Editor, Renal and Extracorporeal Blood Treatment ASAIO Journal. All remaining authors have nothing to disclose.